Immunomedics

Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug Remdesivir in patients with severe coronavirus disease (Covid-19), during the outbreak of the coronavirus disease (Covid-19), in Oceanside, California, US, April 29, 2020.
World+Biz

Gilead to buy cancer drugmaker Immunomedics for $21 billion

Immunomedics is also on track to file for regulatory approval for Trodelvy in Europe in the first half of 2021